Please login to the form below

AZD3293

This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down

Latest news

Biogen rises on more positive data for Alzheimer's candidate

compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
Lilly sinks as solanezumab fails again in Alzheimer's

AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

AMARANTH could be first treatment to target underlying mechanism. . AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a ... AZ and Lilly are already carrying out one phase
Eisai and Biogen plan phase III trials for Alzheimer's drug

others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch October 2016

Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Writers (All levels) Editorial / Scientific Leads & ...: Highly Competitive Remuneration packages

Editorial Director - UK, , EUROPE, REMOTE.: Highly Competitive Salary, Bonus &Benefits

Senior Account Management Trainer, Medical Communications, Londo...: Highly competitive salary

Account Director, Medical & Brand Communications, London/ SE...: Highly competitive salary

Publications Trainer, Medical Communications Agency, UK, Full or...: £50-75K

Entry Level Account Executive – Healthcare Advertising – London...: Salary TBC

Digital Engagement Strategist, Healthcare Brand Communications, ...: £75-90K

CEO Pricing & Market Access, UK: Six figure salary

Freelance Scientific Director, Medical Communications, London/ S...: Highly competitive salary

Group Account Director, Medical/ Commercial launch, Healthcare c...: circa £90K

Senior Account Director, Medical & Brand Communications, Lon...: Highly competitive salary

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Medcomms Trainer, Medical Communications Agency, UK, Full or Par...: £50-75K

Senior & Principal Medical Writers Medical Communications - ...: Salary TBC

PMHub

Add my company

JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Health literacy in the time of COVID-19: In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare: ...
How to pick the perfect training program for your healthcare professionals: You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...

Email:
Password:

Please login to the form below

AZD3293

COVID-19 Updates and Daily News

Featured jobs

Quick links